ESOCAP ANNOUNCES PUBLICATION OF “Stability of Free and Liposomal Encapsulated RNA on a Mucoadhesive PVA Polymer for Esophageal RNA Drug Targeting Using the EsoCap System”

Basel, Switzerland, June 27, 2024

EsoCap has announced that scientists from the University of Greifswald have published highly promising data for the development of RNA drugs for localized use in the oesophagus, utilizing the EsoCap System.

The core component is a mucoadhesive film that carries the RNA drug and is precisely applied to the oesophagus. Research into the stability and properties of naked and liposomal-encapsulated RNA on mucoadhesive polymer film revealed that the RNAs remain stable. These findings pave the way for RNA drug development for oesophageal diseases and their administration via the EsoCap system (Weide et al., Advanced Therapeutics 2024, 2300446).

“Research in the area of RNA has been particularly active over the last years,” said Prof. Werner Weitschies, head of the Biopharmaceutics group at the Center of Drug Absorption and Transport. “Our results form the basis for future research into RNA therapies for oesophageal diseases and offer a promising perspective for innovative drug formulations on the EsoCap system.”

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap’s vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique and innovative topical drug delivery platform.

Effective topical treatment of the esophagus is extremely difficult to achieve with the current standard of care, due to the ultra-short drug contact time of one to two seconds from the mouth to the stomach. Lead candidate ESO-101 has received Orphan Drug Designation from the U.S. Food & Drug Administration (FDA) for the treatment of EoE and is in clinical development for this indication.

EsoCap has developed a unique, proprietary drug delivery platform allowing the efficient topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract. EsoCap has a strong and broad intellectual property position.

For more information, please visit www.esocapbiotech.com and follow EsoCap on LinkedIn and Twitter.

About the University of Greifswald

Across numerous departments and disciplines, the University of Greifswald community advances ideas and innovations that enrich human life. The University’s departments encompass a wide range of fields, including General and Clinical Pharmacology, Biopharmaceutics and Pharmaceutical Technology, Pharmaceutical Biotechnology, and all clinical disciplines. The Center of Drug Absorption and Transport (C_DAT) is an internationally recognized center of expertise, in which research groups from the University of Greifswald and University Medical Center Greifswald investigate the processes of absorption and transport of drugs through to their desired - and unwanted - sites of effect in the human body.

The C_DAT is respected worldwide and is a leading center of excellence for drug absorption and transport in Europe.
Contact:
Isabelle Racamier, CEO
EsoCap AG
Malzgasse 9
4052 Basel
Switzerland
isabelle.racamier@esocapbiotech.com